APA (7th ed.) Citation

A. S. Kolbin, I. A. Vilum, М. A. Proskurin, & Yu. E. Balykina. (2017). PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS. IRBIS LLC.

Chicago Style (17th ed.) Citation

A. S. Kolbin, I. A. Vilum, М. A. Proskurin, and Yu. E. Balykina. PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS. IRBIS LLC, 2017.

MLA (9th ed.) Citation

A. S. Kolbin, et al. PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS. IRBIS LLC, 2017.